These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30986119)

  • 1. Evaluation of the Efficacy and Safety of A Novel 0.05% Cyclosporin A Topical Nanoemulsion in Primary Sjögren's Syndrome Dry Eye.
    Kang MJ; Kim YH; Chou M; Hwang J; Cheon EJ; Lee HJ; Chung SH
    Ocul Immunol Inflamm; 2020 Apr; 28(3):370-378. PubMed ID: 30986119
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye.
    Park CH; Kim MK; Kim EC; Kim JY; Kim TI; Kim HK; Song JS; Yoon KC; Lee DH; Lee HK; Chung TY; Choi CY; Kim HS
    Korean J Ophthalmol; 2019 Aug; 33(4):343-352. PubMed ID: 31389210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
    Demiryay E; Yaylali V; Cetin EN; Yildirim C
    Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study.
    Yoon CH; Lee HJ; Lee EY; Lee EB; Lee WW; Kim MK; Wee WR
    J Korean Med Sci; 2016 Jul; 31(7):1127-35. PubMed ID: 27366013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
    Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study.
    Moscovici BK; Holzchuh R; Sakassegawa-Naves FE; Hoshino-Ruiz DR; Albers MB; Santo RM; Hida RY
    Cont Lens Anterior Eye; 2015 Oct; 38(5):373-8. PubMed ID: 25956572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops (II) in the Treatment of Dry Eye Associated with Primary Sjögren's Syndrome.
    Gao M; Zhao L; Liang R; Zhu Q; Zhao Q; Kong X
    Ocul Immunol Inflamm; 2023 Oct; 31(8):1662-1668. PubMed ID: 35914303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between systemic activity ındex and dry eye severity in patients with primary Sjögren syndrome.
    Ozek D; Kemer OE; Omma A
    Arq Bras Oftalmol; 2019; 82(1):45-50. PubMed ID: 30403265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sjögren's syndrome associated dry eye in a mouse model is ameliorated by topical application of integrin α4 antagonist GW559090.
    Contreras-Ruiz L; Mir FA; Turpie B; Krauss AH; Masli S
    Exp Eye Res; 2016 Feb; 143():1-8. PubMed ID: 26463157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
    Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
    Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the first tear film break-up point in Sjögren's syndrome and non-Sjögren's syndrome dry eye patients.
    Zhao S; Le Q
    BMC Ophthalmol; 2022 Jan; 22(1):1. PubMed ID: 34980014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
    Stevenson D; Tauber J; Reis BL
    Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca.
    Pflugfelder SC; Jones D; Ji Z; Afonso A; Monroy D
    Curr Eye Res; 1999 Sep; 19(3):201-11. PubMed ID: 10487957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of platelet-rich plasma and autologous-serum eye drops for dry eye in primary Sjögren's syndrome: a randomized trial.
    Kang MJ; Lee JH; Hwang J; Chung SH
    Sci Rep; 2023 Nov; 13(1):19279. PubMed ID: 37935760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prospective, monocentric, uncontrolled study of efficacy, tolerance and adherence of cyclosporin 0.1 % for severe dry eye syndrome].
    Boujnah Y; Mouchel R; El-Chehab H; Dot C; Burillon C; Kocaba V
    J Fr Ophtalmol; 2018 Feb; 41(2):129-135. PubMed ID: 29449025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome.
    Devecı H; Kobak S
    Int Ophthalmol; 2014 Oct; 34(5):1043-8. PubMed ID: 24442759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association of Serum Vitamin D Level With the Severity of Dry Eye Parameters in Primary Sjögren Syndrome.
    Lee JH; Kim SJ; Byun YS; Lee J; Park SH; Chung SH
    Cornea; 2020 Jun; 39(6):702-705. PubMed ID: 31868853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
    Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
    Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome.
    Moawad P; Shamma R; Hassanein D; Ragab G; El Zawahry O
    Eur J Ophthalmol; 2022 Jan; 32(1):673-679. PubMed ID: 33530719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation.
    Cordero-Coma M; Anzaar F; Sobrin L; Foster CS
    Ocul Immunol Inflamm; 2007; 15(2):99-104. PubMed ID: 17558834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.